Charter
People
Creations
Perspectives
Governance
Contact Us
Investor Login
EN
EN
JP
Our Perspectives
View all
Catalys Pacific News
Portfolio News
October 30, 2024
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
October 21, 2024
Aculys Pharma Delivers Positive Results in Domestic Phase III Clinical Trial of Pitolisant for Narcolepsy Patients
October 10, 2024
Arialys Therapeutics Announces First Participants Dosed in a Phase 1 Clinical Trial of ART5803, a Precision Medicine for the Treatment of Autoimmune Neuropsychiatric Diseases
September 25, 2024
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension
September 2, 2024
Aculys Pharma Files New Drug Application for Diazepam Nasal Spray in Japan: An Antiepileptic Drug for the Treatment of Epileptic Seizures
August 20, 2024
Pathalys Pharma Secures $105 Million Series B Financing
July 30, 2024
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
July 24, 2024
Transposon Announces Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia
July 22, 2024
Aculys Pharma Completes Patient Enrollment for Phase 3 Clinical Trial on Pitolisant in Patients with Narcolepsy
July 18, 2024
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
July 18, 2024
Renalys Pharma announces first patient dosed in registrational Phase III clinical trial of sparsentan for IgA nephropathy in Japan
July 17, 2024
Renalys Pharma Closes ¥6.0Bn Series A Financing to Advance Kidney Disease Treatments Across Asia
July 9, 2024
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
May 29, 2024
Transposon Receives US FDA Fast Track Designation for TPN-101 for Progressive Supranuclear Palsy
May 7, 2024
The Japan Kidney Association and Renalys Pharma Form Collaborative Agreement to Overcome Kidney Disease
April 7, 2024
Renalys Pharma Submits an IND Application for a Phase III Clinical Trial of sparsentan for IgA Nephropathy in Japan
February 13, 2024
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
February 13, 2024
Transposon Announces Final Results from a Phase 2 Study of its LINE-1 Reverse Transcriptase Inhibitor TPN-101 for the Treatment of Progressive Supranuclear Palsy and Interim Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia
February 8, 2024
Mineralys Therapeutics Announces $120 Million Private Placement Financing
January 25, 2024
Renalys Pharma Is Launched To Bring New Innovative Medicines To Patients In Japan and Other Countries In Asia
November 1, 2023
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
October 30, 2023
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
October 18, 2023
Aculys Pharma delivers positive Phase 3 clinical study interim analysis result of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures
October 1, 2023
Catalys Pacific Strengthens Company Creation Team with New Partner
September 20, 2023
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
September 12, 2023
Arialys Therapeutics Launches to Lead the Development of New Precision Medicines for Autoimmune Neuropsychiatric Diseases
September 10, 2023
Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension
August 18, 2023
Catalys Pacific Adds Experienced Pharmaceutical Executive as Advisor
July 7, 2023
Catalys Pacific Adds Experienced Pharmaceutical and Biotech Executive as Advisor
February 14, 2023
Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 9, 2023
Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering
January 24, 2023
Aculys Pharma Initiates a Phase 3 Trial of pitolisant Treating Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Syndrome
January 18, 2023
Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 Studies
January 8, 2023
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
November 10, 2022
Aculys Pharma initiates a phase 3 clinical study of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures
November 8, 2022
Aculys Pharma initiates a phase 3 clinical study of the histamine H3 receptor antagonist/inverse agonist pitolisant in patients with narcolepsy in Japan
May 3, 2022
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
May 3, 2022
HilleVax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 2, 2022
HilleVax Announces Initiation of Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants
March 30, 2022
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
March 28, 2022
Aculys Pharma Closes US$24 Million Series B Financing
March 23, 2022
Catalys Pacific Launches Kirilys Therapeutics as a Multi-asset Precision Oncology Company
March 10, 2022
Catalys Pacific Calls for Economical Disengagement from Russian Industry
March 2, 2022
Pathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease
February 17, 2022
Catalys Pacific Adds Experienced Pharmaceutical Executive to Life Sciences Team
February 4, 2022
Aculys Pharma Initiated a Phase 1 Clinical Trial of pitolisant, a histamine H3 receptor antagonist / inverse agonist, in Japan
January 26, 2022
Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of VALTOCO®
October 29, 2021
Aculys Pharma Closes US$60 Million Series A Financing Led by SoftBank Vision Fund 2
October 18, 2021
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
September 8, 2021
Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection
September 8, 2021
HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate
August 9, 2021
Remembering Catalys Pacific Industry Advisor Tadataka ‘Tachi’ Yamada, MD (1945-2021)
April 29, 2021
Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints
April 6, 2021
Mineralys Therapeutics Closes $40 Million Series A Funding
January 19, 2021
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
November 30, 2020
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial
November 4, 2020
Catalys Pacific Strengthens Company Creation Team with New Operating Partner
July 16, 2020
Domain Associates and Catalys Pacific Launch Exalys Therapeutics to Develop Portfolio of Next-Generation EP4 Antagonists
June 19, 2020
Catalys Pacific Strengthens Company Creation Team with New Industry Advisor
October 24, 2019
Phathom Pharmaceuticals Announces Pricing of Initial Public Offering and Begin trading on the Nasdaq
July 23, 2019
Japanese Foreign Minister’s Commendations for FY 2019 to Dr. Slingsby, Founder & Managing Partner of Catalys Pacific
June 17, 2019
Catalys Pacific Launches in Japan to Advance Early-Stage Life Sciences Innovation by Creating and Investing in Global Companies
May 14, 2019
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals
Creations
View all
Phathom Pharmaceuticals
Going Beyond to Advance Treatments for Patients with Acid-Related Disorders
Transposon
Developing Innovative Treatments for LINE-1 associated Neurodegenerative Disease
OUR CREW
Learn more